Biogen, Eisai Alzheimer’s drug gets full FDA approval


The U.S. Food and Drug Administration has granted full, traditional approval to an Alzheimer's disease drug made by Eisai Inc. and Biogen Inc., six months after it won conditional approval from the same agency.

Previous Newsmaker: Faith Voinovich of Ohio Innovation Fund named 'rising star' after picking less-worn paths
Next Future of Fairfield: How business, real estate can make a comeback